Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.61 |
| ▸ | PI4KA | P42356 | 3/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11010323 | 0.98 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11012652 | 0.98 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11008256 | 0.95 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL30289754 | 0.89 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL218588 | 0.89 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5015473 | 0.86 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL4906617 | 0.86 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL20445820 | 0.86 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11222112 | 0.85 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5017547 | 0.84 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADCY5PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| CN-1234718-C | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-01-04 | — | — | CN | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| CN-1464880-A | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-12-31 | — | — | CN | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
| US-4542137-A | NONEXPLOSIVE, CARDIOVASCULAR | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1985-09-17 | — | — | US | disclosed |
| EP-0044927-B1 | ALKYLAMINO-DESOXY-1,4;3,6-DIANHYDRO-HEXITE-NITRATE SUBSTITUTED BY PURINE BASES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0044927-A1 | Alkylamino-desoxy-1,4;3,6-dianhydro-hexite-nitrate substituted by purine bases, process for their preparation and their pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | ADORA2A 4404/4885ADORA1 3037/4885ADORA2B 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.